SCHEMBL27189751

SCHEMBL27189751

COCOCCc1ccc(OCc2ccccc2)c2c(C(=O)C(=O)N(C)C)c[nH]c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.38
LTA4H P09960 1/20 0.38
PLA2G2A P14555 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
CYP2C9 P11712 3/20 0.35
MAPT P10636 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
APP P05067 4/20 0.35
LRRK2 Q5S007 1/20 0.35
PTGER1 P34995 1/20 0.34
PTGER4 P35408 1/20 0.34
PTGER3 P43115 1/20 0.34
PTGER2 P43116 1/20 0.34
BRD4 O60885 1/20 0.34
LTB4R Q15722 1/20 0.33
LTB4R2 Q9NPC1 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27189543 0.87 HTR2A (0.41) HTR2ALTA4HPLA2G2ATRPM8CYP2C9
SCHEMBL27189560 0.82 PTPN1 (0.39) HTR2ALTA4HPLA2G2ATRPM8CYP2C9
SCHEMBL27189618 0.81 MAPT (0.44) HTR2ALTA4HPLA2G2ATRPM8CYP2C9
SCHEMBL27189571 0.80 TDP1 (0.40) HTR2ALTA4HPLA2G2ATRPM8CYP2C9
SCHEMBL27189752 0.80 HTR2A (0.59) HTR2ALTA4HPLA2G2ATRPM8CYP2C9
SCHEMBL12558840 0.75 HTR2A (0.57) HTR2ACYP2C9MAPTCYP2C19SMN1; SMN2
SCHEMBL30368570 0.73 LRRK2 (0.46) HTR2ACYP2C9MAPTCYP2C19SMN1; SMN2
SCHEMBL25748377 0.73 SMN1; SMN2 (0.41) HTR2ATRPM8CYP2C9MAPTCYP2C19
SCHEMBL25748392 0.72 MAPT (0.41) HTR2ATRPM8CYP2C9MAPTCYP2C19
SCHEMBL25748397 0.71 MAPT (0.42) TRPM8CYP2C9MAPTCYP2C19SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059217-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF BRIGHT MINDS BIOSCIENCES INC. (CA) 2025-02-20 US disclosed
CN-117897376-A Heterocyclic compounds and process for preparing same 光明智慧生物科学公司 2024-04-16 CN disclosed
EP-4347561-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF Bright Minds Biosciences Inc. (CA) 2024-04-10 EP disclosed
WO-2022246554-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF BRIGHT MINDS BIOSCIENCES INC. (CA) 2022-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059217-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF OPRL1, OPRK1, CNR2 HTR2A 413/4885LTA4H 1732/4885PLA2G2A 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.